30398
チトクロームC ウシ心臓由来
≥95% (GE)
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
Form:
powder or crystals
Assay:
≥95% (GE)
Biological source:
bovine heart
biological source
bovine heart
assay
≥95% (GE)
form
powder or crystals
technique(s)
activity assay: suitable
impurities
≤5% cytochrome c reduced
solubility
H2O: 10 mg/mL, clear, dark red-brown
UniProt accession no.
storage temp.
−20°C
Gene Information
cow ... CYCS(510767)
類似した製品をお探しですか？ 訪問 製品比較ガイド
Preparation Note
Prepared by a procedure using TCA.
Other Notes
Sales restrictions may apply.
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
30398-1G: + 30398-250MG: + 30398-VAR: + 30398-BULK:
jan
Why is the reduction of NO in cytochrome c dependent nitric oxide reductase (cNOR) not electrogenic?
Margareta R A Blomberg et al.
Biochimica et biophysica acta, 1827(7), 826-833 (2013-04-27)
The membrane-bound enzyme cNOR (cytochrome c dependent nitric oxide reductase) catalyzes the reduction of NO in a non-electrogenic process. This is in contrast to the reduction of O2 in cytochrome c oxidase (CcO), the other member of the heme-copper oxidase
Alexander N Volkov et al.
Biochemistry, 52(13), 2165-2175 (2013-03-23)
Here we present the preparation, biophysical characterization, and nuclear magnetic resonance (NMR) spectroscopy study of yeast cytochrome c peroxidase (CcP) constructs with enhanced solubility. Using a high-yield Escherichia coli expression system, we routinely produced uniformly labeled [(2)H,(13)C,(15)N]CcP samples with high
Shujun Yuan et al.
Biochemistry, 52(13), 2319-2327 (2013-03-26)
Apoptosome assembly is highly regulated in the intrinsic cell death pathway. To better understand this step, we created an improved model of the human apoptosome using a crystal structure of full length Apaf-1 and a single particle, electron density map
Gongquan Li et al.
Biochemical and biophysical research communications, 434(4), 809-814 (2013-04-25)
Small-molecule Bcl-2/Bcl-xL inhibitor Navitoclax represents a promising cancer therapeutic since preclinical and clinical studies with Navitoclax have demonstrated strong anticancer activity in several types of cancers. However, because Navitoclax has a low binding affinity to Mcl-1, anticancer activity by Navitoclax
M Harjai et al.
Anaesthesia and intensive care, 41(2), 175-183 (2013-03-28)
Sepsis remains as a leading cause of death in critically ill patients. Unfortunately, there have been very few successful specific therapeutic agents that can significantly reduce the attributable mortality and morbidity of sepsis. Developing novel therapeutic strategies to improve outcomes
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）